natgillin/translations-raw huggingface dataset:
As neural tube defects occur within the first 4 weeks of foetal development (at which time neural tubes are sealed), this potential risk would concern women exposed to efavirenz during the first trimester of pregnancy. 
Ker pa okvare nevralne cevi nastanejo v prvih štirih tednih razvoja zarodka (ko se nevralna cev zapre), to možno tveganje zadeva samo ženske, ki so efavirenzu izpostavljene v prvem trimesečju nosečnosti.
Biliary fibrosis has been observed in rats. 
Pri podganah so opažali biliarno fibrozo.
Carcinogenicity studies showed an increased incidence of hepatic and pulmonary tumours in female mice, but not in male mice. 
Študije karcinogenosti so pokazale povečano pojavnost jetrnih in pljučnih tumorjev pri mišjih samicah, ne pa pri mišjih samcih.
Five of these NNRTI-resistant isolates were found to have K103N or a valine-toisoleucine substitution at position 108 (V108I) in RT. Three of the efavirenz treatment failure isolates tested remained sensitive to efavirenz in cell culture and were also sensitive to nevirapine and delavirdine. 
Pri petih od teh na NNRTI-je rezistentnih izolatov so našli substitucijo K103N ali substitucijo valin-v-izolevcin na položaju 108 (V108I) na RT. Trije od teh testiranih izolatov iz neuspešnega zdravljenja z efavirenzem so ostali občutljivi na efavirenz v celični kulturi in so bili občutljivi tudi na nevirapin in delavirdin.
If you have taken SUSTIVA or the combination tablet containing efavirenz, emtricitabine, and tenofovir during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. 
Če zdravilo SUSTIVA ali kombinirane tablete, ki vsebujejo efavirenz, emtricitabin in tenofovir, jemljete med nosečnostjo, bo zdravnik morda naročil redne krvne preiskave in druge diagnostične teste za spremljanje razvoja otroka.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicinal product. 
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze ne smejo jemati tega zdravila.
7 Carefully pull the cap away from the body of the capsule (illustration c). 
7 Previdno povlecite pokrovček s telesa kapsule (slika c).
15 Do not give the child any additional food for 2 hours. 
15 Naslednji 2 uri otroku ne smete dati dodatne hrane.
Most cases occurred in patients who already had liver disease, but there have been a few reports in patients without any existing liver disease. 
Večina primerov se je pojavila pri bolnikih, ki so že imeli bolezen jeter, nekaj primerov pa je bilo tudi pri bolnikih brez predhodne bolezni jeter.
It is recommended that the tablet be swallowed whole with water. 
Priporočamo, da tableto pogoltnete celo, z vodo.
Study Number/ Treatment Regimensb n % (95% C.I.c) 
Številka študije/ režimi zdravljenjab n % (95-odstotni IZc)
Antibiotics, including the following types: macrolides, fluoroquinolones or imidazole. 
antibiotiki, vključno z naslednjimi skupinami: makrolidi, fluorokinoloni ali imidazoli.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and pneumonia caused by Pneumocystis jiroveci (formerly known as Pneumocystis carinii). 
Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami in pljučnica, povzročena s Pneumocystis jiroveci (nekoč znana kot Pneumocystis carinii).
The potency of efavirenz in cell culture against viral variants with amino acid substitutions at positions 48, 108, 179, 181 or 236 in RT or variants with amino acid substitutions in the protease was similar to that observed against wild type viral strains. 
Učinkovitost efavirenza v celičnih kulturah proti virusnim različicam z aminokislinskimi substitucijami na mestih 48, 108, 179, 181 ali 236 na RT ali različicam z aminokislinskimi substitucijami na proteazi je bila podobna njegovi učinkovitosti proti divjim tipom virusnih sevov.
In addition, your doctor may prescribe a higher dose of SUSTIVA. 
Poleg tega vam bo zdravnik morda predpisal večji odmerek zdravila SUSTIVA.
Study 020 showed similar activity in NRTI-experienced patients over 24 weeks. 
Študija 020 je pri bolnikih, ki so se že zdravili z NRTI-ji, po 24 tednih pokazala podobno aktivnost.
2 Wash and dry your hands before and after preparing the capsule sprinkle. 
2Pred pripravo posutja kapsule in po njej si umijte roke in jih osušite.
One child was reported to have a neural tube defect, and the frequency and pattern of other birth defects were similar to those seen in children exposed to non-efavirenz-containing regimens, as well as those in HIV negative controls. 
Pri enem otroku so poročali o okvari nevralne cevi, pogostnost in vzorec drugih prirojenih napak pa sta bila podobna kot pri tistih otrocih, ki so bili izpostavljeni režimu zdravljenja brez efavirenza, in kot v kontrolnih skupinah, ki niso bile okužene s HIV.
if you are currently taking any of the following medicines (see also “Other medicines and Sustiva”): 
če trenutno jemljete katero koli od naslednjih zdravil (glejte tudi "Druga zdravila in zdravilo Sustiva"):
Thirteen isolates previously characterised as efavirenz-resistant were also resistant to nevirapine and delavirdine. 
Trinajst izolatov, ki so jih poprej označili kot rezistentne na efavirenz, je bilo rezistentnih tudi na nevirapin in delavirdin.
If you take these two medicines together, the dose of voriconazole must be increased and the dose of efavirenz must be reduced. 
Če jemljete hkrati obe zdravili, je treba odmerek vorikonazola povečati in odmerek efavirenza zmanjšati.
In some cases, your doctor may need to adjust your dose or check your blood levels. 
V nekaterih primerih bo zdravnik morda moral prilagoditi odmerek ali preveriti količino zdravil v krvi.
No dose adjustment is necessary for any of these medicinal products. 
Prilagoditev odmerka ni potrebna za nobeno od teh zdravil.
In the long-term study (006), 1% of patients in each treatment arm discontinued because of liver or biliary system disorders. 
V dolgoročni študiji (006) je 1 % bolnikov v vsakem kraku prekinilo zdravljenje zaradi motenj v delovanju jeter, žolčnika ali žolčevodov.
SUSTIVA must be taken with other medicines that act against the HIV virus. 
Zdravilo SUSTIVA je treba jemati skupaj z drugimi zdravili, ki delujejo proti virusu HIV.
Since no dose recommendation for itraconazole can be made, alternative antifungal treatment should be considered. 
Ker za itrakonazol ni mogoče dati priporočila za odmerjanje, je treba pretehtati možnost uporabe drugega antimikotika.
A third isolate which carried a substitution at position 236 of RT was not cross-resistant to efavirenz. 
Tretji izolat, s substitucijo na položaju 236 na RT, ni bil navzkrižno rezistenten na efavirenz.
uncommon hypercholesterolaemia* 
občasni hiperholesterolemija*
Precautions to prevent transmission should be taken in accordance with national guidelines. 
V skladu z nacionalnimi smernicami je treba uporabiti varnostne ukrepe za preprečevanje prenosa
Titanium dioxide (E171) 
Titanov dioksid (E171)
Efavirenz is a non-competitive inhibitor of HIV-1 reverse transcriptase (RT) and does not significantly inhibit HIV-2 RT or cellular DNA polymerases (α, β, γ or δ). 
Efavirenz je nekompetitivni zaviralec reverzne transkriptaze (RT) HIV-1 in ne zavira pomembno RT HIV-2 ali celičnih polimeraz DNA (α, β, γ ali δ).
Based on this new data, the PRAC considers that the statement that the interaction between etonogestrel and efavirenz has not been studied is no longer valid and that this statement should be removed from the SmPC of all efavirenz-containing products. 
Na podlagi teh novih podatkov odbor PRAC meni, da navedba, da medsebojnega delovanja etonogestrela in efavirenza niso preučili, ne drži več, zato je treba to navedbo odstraniti iz vseh povzetkov glavnih značilnosti zdravila za vsa zdravila, ki vsebujejo efavirenz.
Efavirenz has also been shown to induce UGT1A1. 
Pokazalo se je, da efavirenz inducira tudi UGT1A1.
The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded. 
Ni znano, da bi taka povezava imela klinične posledice, vendar pa možnost za povečanje pogostnosti in resnosti z efavirenzem povezanih neželenih učinkov ne more biti izključena.
Carcinogenicity studies in male mice, male and female rats were negative. 
Študije karcinogenosti pri mišjih samcih ter samcih in samicah podgan so bile negativne.
Concomitant administration of sofosbuvir/velpatasvir with efavirenz resulted in a reduction (approximately 50%) in the systemic exposure of velpatasvir. 
Sočasna uporaba efavirenza in sofosbuvira/velpatasvira je povzročila zmanjšanje (približno 50-odstotno) sistemske izpostavljenosti velpatasviru.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement. 
Bolnikom je treba svetovati, naj poiščejo zdravniško pomoč, če se pojavijo bolečine v sklepih, togost sklepov ali težave z gibljivostjo.
Medicines used to lower blood fats (also called statins): atorvastatin, pravastatin, simvastatin. 
Zdravila za znižanje maščob v krvi (imenovana tudi statini): atorvastatin, pravastatin, simvastatin.
It is recommended that the capsule be swallowed whole with water. 
Priporočamo, da kapsulo pogoltnete celo, z vodo.
Efavirenz plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isoenzyme. 
Plazemska izpostavljenost efavirenza je lahko povečana pri bolnikih s homozigotno G516T genetsko različico izoencima CYP2B6.
Rare (affects 1 to 10 users in 10,000) itchy rash caused by a reaction to sunlight liver failure, in some cases leading to death or liver transplant, has occurred with efavirenz. 
Redki (pojavijo se pri 1 do 10 od 10.000 bolnikov) srbeč izpuščaj, ki nastane zaradi reakcije na sonce odpoved jeter, ki je v določenih primerih smrtna ali vodi do presaditve jeter, se je pojavila pri uporabi efavirenza.
Cross resistance profiles for efavirenz, nevirapine and delavirdine in cell culture demonstrated that the K103N substitution confers loss of susceptibility to all three NNRTIs. 
Profili navzkrižne rezistence na efavirenz, nevirapin in delavirdin v celičnih kulturah so pokazali, da substitucija K103N povzroči izgubo občutljivosti na vse tri NNRTI-je.
FURTHER INFORMATION 
DODATNE informacije
In a single-dose study, half life was doubled in the single patient with severe hepatic impairment (Child Pugh Class C), indicating a potential for a much greater degree of accumulation. 
V študiji z enkratnim odmerjanjem je bil pri edinem bolniku s hudo jetrno okvaro (razred C po Child Pugh-u) razpolovni čas dvakrat daljši, kar kaže na možnost veliko večje akumulacije.
If there is evidence of worsening liver disease or persistent elevations of serum transaminases to greater than 5 times the upper limit of the normal range, the benefit of continued therapy with efavirenz needs to be weighed against the potential risks of significant liver toxicity. 
Če pride do poslabšanja bolezni jeter ali če vrednosti serumskih transaminaz vztrajajo na več kot 5-kratni zgornji meji normalnih vrednosti, je treba pretehtati koristi nadaljevanja zdravljenja z efavirenzem z možnim tveganjem pomembne toksičnosti tega zdravila za jetra.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products. 
V primeru sočasnega protivirusnega zdravljenja z zdravili proti hepatitisu B ali C, prosimo, preberite tudi ustrezne Povzetke glavnih značilnosti teh zdravil.
Immunosuppressants such as cyclosporine, sirolimus, or tacrolimus (medicines used to prevent organ transplant rejection): when you start or stop taking SUSTIVA, your doctor will closely monitor your plasma levels of the immunosuppressant and may need to adjust its dose. 
Imunosupresive, kot so ciklosporin, sirolimus ali takrolimus (zdravila za preprečitev zavrnitve presajenega organa): ko boste začeli ali prenehali jemati zdravilo SUSTIVA, bo zdravnik skrbno nadzoroval količino imunosupresiva v plazmi in bo morda moral prilagoditi njegov odmerek.
Analysis of long-term data showed that, beyond 24 weeks of therapy, the incidences of new-onset nervous system symptoms among efavirenz-treated patients were generally similar to those in the control arm. 
Analiza dolgoročnih podatkov je pokazala, da je bila pojavnost novih simptomov živčnega sistema po več kot 24 tednih zdravljenja pri bolnikih, zdravljenih z efavirenzem, na splošno podobna kot v kontrolnem kraku.
Give the mixture to the child as soon as possible, but no more than 30 minutes after mixing. 
Otrok naj mešanico zaužije takoj, ko je mogoče, vendar ne kasneje kot 30 minut po pripravi.
The free concentration of efavirenz required for 90 to 95% inhibition of wild type or zidovudineresistant laboratory and clinical isolates in vitro ranged from 0.46 to 6.8 nM in lymphoblastoid cell lines, peripheral blood mononuclear cells (PBMCs) and macrophage/monocyte cultures. 
Koncentracija prostega efavirenza, potrebna za 90 % do 95 % in vitro inhibicijo laboratorijskih in kliničnih izolatov divjega tipa ali tistih, ki so rezistentni na zidovudin, je bila v območju od 0,46 do 6,8 nM, in sicer v limfoblastoidnih celičnih linijah, perifernih krvnih enojedrnih celicah (PBMC) in v kulturah makrofagov/monocitov.
signs of dizziness, difficulty sleeping, drowsiness, difficulty concentrating or abnormal dreaming. 
znake omotice, oteženo spanje, zaspanost, težave s koncentracijo ali nenormalne sanje.
If you notice any of these symptoms please inform your doctor. 
Če opazite katerega od teh simptomov, prosimo, da obvestite zdravnika.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). 
Poročali so o primerih osteonekroze, še zlasti pri bolnikih s splošno znanimi dejavniki tveganja, napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART).
Study 020 
Študija 020 24 tednov
Patients should be monitored carefully for dose-related adverse reactions, especially nervous system symptoms (see sections 4.3 and 4.4). 
Bolnike je treba pozorno spremljati zaradi od odmerka odvisnih neželenih učinkov, še posebej simptomov živčnega sistema (glejte poglavji 4.3 in 4.4).
Plasma concentrations and effects of warfarin or acenocoumarol are potentially increased or decreased by efavirenz. 
Plazemske koncentracije in učinki varfarina ali acenokumarola se lahko zaradi efavirenza povečajo ali zmanjšajo.
For blisters: 2 years. 
Za pretisne omote: 2 leti
The dose of nelfinavir was 750 mg given three times a day. 
Odmerek nelfinavirja je bil 750 mg trikrat na dan.
While the clinical significance of decreased indinavir concentrations has not been established, the magnitude of the observed pharmacokinetic interaction should be taken into consideration when choosing a regimen containing both efavirenz and indinavir. 
Kliničnega pomena zmanjšanih koncentracij indinavirja niso ugotovili, vendar je treba stopnjo opažene farmakokinetične interakcije upoštevati pri izbiri režima zdravljenja, pri katerem se uporabljata oba - efavirenz in indinavir.
There were insufficient data to determine whether moderate or severe hepatic impairment (Child-Pugh Class B or C) affects efavirenz pharmacokinetics. 
Podatkov za določitev, ali zmerna ali huda okvara jeter (razred B ali C po Child Pugh-u) vpliva na farmakokinetiko efavirenza, ni bilo dovolj.
Patients who are receiving concomitant anticonvulsant medicinal products primarily metabolised by the liver, such as phenytoin, carbamazepine and phenobarbital, may require periodic monitoring of plasma levels. 
Pri bolnikih, ki sočasno prejemajo antikonvulzive, ki se primarno metabolizirajo v jetrih, kot so fenitoin, karbamazepin in fenobarbital, je lahko potrebno periodično spremljanje plazemskih koncentracij.
Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after failure of regimens containing SUSTIVA. 
Čeprav navzkrižna rezistenca efavirenza z ZP ni dokumentirana, trenutno nimamo dovolj podatkov o učinkovitosti uporabe kombiniranega zdravljenja, ki vključuje ZP, po neuspelem zdravljenju z režimom, ki je vključeval tudi zdravilo SUSTIVA.
An alternative anticonvulsant should be considered. 
Pretehtati je treba možnost uporabe drugega antikonvulziva.
In HIV-1 infected patients (n = 6), the pharmacokinetics of indinavir and efavirenz were generally comparable to these uninfected volunteer data. 
Pri bolnikih, okuženih s HIV-1 (n = 6), sta bili farmakokinetiki indinavirja in efavirenza primerljivi s podatki za neokužene prostovoljce.
In a study of uninfected volunteers, a representative nervous system symptom had a median time to onset of 1 hour post-dose and a median duration of 3 hours. 
V študiji pri neokuženih prostovoljcih, se je značilen simptom živčnega sistema pojavil 1 uro (mediana vrednost) po odmerku in je trajal 3 ure (mediana vrednost).
Efavirenz must not be used as a single agent to treat HIV or added on as a sole agent to a failing regimen. 
Efavirenza se ne sme uporabljati kot samostojno zdravilo za zdravljenje HIV, prav tako se ga kot edinega ne sme dodati k neuspelemu režimu zdravljenja.
Laboratory tests should be performed to evaluate their liver disease at periodic intervals (see section 4.2). 
Za oceno stopnje jetrne bolezni je treba periodično opravljati laboratorijske teste (glejte poglavje 4.2).
The single substitutions which led to the highest resistance to efavirenz in cell culture correspond to a leucine-to-isoleucine change at position 100 (L100I, 17 to 22-fold resistance) and a lysine-to-asparagine at position 103 (K103N, 18 to 33-fold resistance). 
Enkratne substitucije, ki so povzročile največjo rezistenco na efavirenz v celični kulturi, so ustrezale spremembi levcina v izolevcin na mestu 100 (L100I, 17 do 22-krat večja rezistenca) in spremembi lizina v asparagin na mestu 103 (K103N, 18 do 33-krat večja rezistenca).
if you are currently taking any of the following medicines(see also “Other medicines and Sustiva”): 
če trenutno jemljetekatero koli od naslednjih zdravil(glejte tudi "Druga zdravila in zdravilo Sustiva"):
A few of the postmarketing reports of hepatic failure, including cases in patients with no pre-existing hepatic disease or other identifiable risk factors, were characterized by a fulminant course, progressing in some cases to transplantation or death. 
V nekaj postmarketinških poročilih o odpovedi jeter, vključno s primeri pri bolnikih brez predhodne bolezni jeter ali drugih odkritih dejavnikov tveganja, je bil opisan tudi fulminantni potek, ki je v nekaterih primerih napredoval do transplantacije ali smrti.
If you stop taking SUSTIVA 
Če ste prenehali jemati zdravilo SUSTIVA
Study ACTG 364 enrolled 196 patients who had been treated with NRTIs but not with PIs or NNRTIs. 
Študija ACTG 364 je vključevala 196 bolnikov, zdravljenih z NRTI, ne pa z ZP ali NNRTI.
If SUSTIVA is started because your current treatment has not prevented the virus from multiplying, another medicine you have not taken before must be started at the same time. 
Če boste začeli z jemanjem zdravila SUSTIVA zato, ker dosedanji način zdravljenja ni preprečil razmnoževanja virusa, morate hkrati začeti jemati tudi drugo protivirusno zdravilo, ki ga do sedaj še niste jemali.
8 Sprinkle the contents of the capsule on the food (illustration d). 
8 Posujte vsebino kapsule po hrani (slika d).
4 Place 1-2 teaspoons of the food in a small container (illustration a). 
4 Dajte 1-2 čajni žlički hrane v majhno posodo (slika a).
When prescribing medicinal products concomitantly with efavirenz, physicians should refer to the corresponding Summary of Product Characteristics. 
Pri predpisovanju zdravil, ki se jemljejo hkrati z efavirenzem, mora zdravnik upoštevati ustrezni Povzetek glavnih značilnosti zdravila.
Psychiatric disorders common abnormal dreams, anxiety, depression, insomnia* 
Psihiatrične motnje pogosti nenormalne sanje, anksioznost, depresija, nespečnost*
Diltiazem or similar medicines (called calcium channel blockers which are medicines typically used for high blood pressure or heart problems): when you start taking SUSTIVA, your doctor may need to adjust your dose of the calcium channel blocker. 
Diltiazem ali podobna zdravila (imenovana zaviralci kalcijevih kanalov in so zdravila, ki se običajno uporabljajo za zvišan krvni tlak ali težave s srcem): ko boste začeli jemati zdravilo SUSTIVA, vam bo zdravnik morda moral prilagoditi odmerek zaviralca kalcijevih kanalov.
There is insufficient information on the effects of efavirenz in newborns/infants. 
O učinkih efavirenza na novorojenčke/dojenčke ni dovolj podatkov.
Your doctor will give you instructions for proper dosing. 
Navodila za pravilno odmerjanje vam bo dal zdravnik.
Nervous system disorders common cerebellar coordination and balance disturbances†, disturbance in attention (3.6%), dizziness (8.5%), headache (5.7%), somnolence (2.0%)* 
Bolezni živčevja pogosti motnje cerebelarne koordinacije in ravnotežja motnje koncentracije (3,6 %), omotica (8,5 %), glavobol (5,7 %), zaspanost (2,0 %)*
Use of efavirenz in combination with saquinavir as the sole protease inhibitor is not recommended. 
Uporabe efavirenza v kombinaciji s sakvinavirjem, kot edinim zaviralcem proteaze, ne priporočamo.
Do not use this medicine after the expiry date which is stated on the bottle or blister and on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in na škatli poleg oznake "Uporabno do" ali "EXP".
Dark yellow, capsule-shaped, printed with “SUSTIVA” on both sides. 
Temno rumene barve, v obliki kapsule in imajo napis "SUSTIVA" na obeh straneh.
The clinical significance of these changes in clarithromycin plasma levels is not known. 
Klinični pomen teh sprememb v koncentracijah klaritromicina v plazmi ni znan.
While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. 
Čepav je bilo dokazano, da učinkovita supresija virusa s protivirusnim zdravljenjem znatno zmanjšuje tveganje za prenos s spolnimi odnosi, ne smemo izključiti rezidualnega tveganja.
This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. 
To je zelo pomembno, kajti če prenehate jemati zdravilo, pa čeprav za kratek čas, lahko začne količina virusa naraščati in postane nadaljnje zdravljenje težje.
In HIV-1 infected patients (n = 9) who received efavirenz 200 to 600 mg once daily for at least one month, cerebrospinal fluid concentrations ranged from 0.26 to 1.19% (mean 0.69%) of the corresponding plasma concentration. 
Pri bolnikih, okuženih s HIV-1 (n = 9), ki so vsaj en mesec dobivali 200 do 600 mg efavirenza enkrat na dan, je bila njegova koncentracija v cerebrospinalni tekočini v območju od 0,26 do 1,19 % (povprečno 0,69 %) ustrezne plazemske koncentracije.
In view of the data presented in the reviewed PSUR, the overall risk-benefit balance of efavirenz is therefore considered unchanged in the approved indications provided that the terms of the marketing authorisation are varied as relevant. 
Ob upoštevanju podatkov, predstavljenih v pregledanem poročilu PSUR, ostaja skupno razmerje med tveganji in koristmi efavirenza za odobrene indikacije nespremenjeno, pod pogojem, da se spremenijo pogoji dovoljenja za promet z zdravilom, kot je ustrezno.
Steps 11-14 must be completed within 30 minutes of mixing: 11 Give the mixture of food and capsule contents to the child, making sure he or she eats the full amount (illustration f). 
Korake 11-14 je treba dokončati v 30 minutah po pripravi mešanice: 11 Mešanico hrane in vsebine kapsule dajte otroku.
The clinical effect of this dose adjustment has not been adequately evaluated. 
Kliničnega učinka take prilagoditve odmerka niso zadostno ovrednotili.